What will be presented is anyone's guess. However, I suspect the results will be positive. With GC touting a possible spinoff of the diagnostic division (by Q2 - if I recall), I just don't see how Lympro will/is not generating revenue for them very soon. Would be great if we get sales data or some sort of BP partnership on top of the Lympro data at the conference.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links